

DBT-Ramalingaswami fellow:

Dr. Rabbind Singh is a Ramalingaswami Re-Entry fellowship awardee and working at Centre for Genomics since April 2017. This fellowship is awarded by the Department of Biotechnology, Government of India to select few Indian researchers working abroad to enable them set-up their independent research team and pursue their research interests in India. After his Ph.D. in Biotechnology from Madurai Kamaraj University, Tamilnadu he moved to France for Post-doctoral research where he worked for more than 4 years. As a Post-doctoral researcher he has worked on various projects related to cancer biology and Molecular Genetics. His post-doctoral work that identified the causative gene for Stormorken Syndrome was received well. His work in France has resulted in twelve research articles published in reputed international journals. Currently he is the Principal investigator of a project to Study the role of SLAMF receptors in Ocular Melanoma. He is also interested in identifying novel signal transduction pathways in various cancers as well.

Publications:

1. **Rabbind Singh A**, Senthamarai Kannan P, Thangavel C, Danda R, Pandian SK, and Dharmalingam K. ChiS histidine kinase negatively regulates the production of chitinase ChiC in *Streptomyces peucetius*. *Microbiological research* 169: 155-162, 2014.
2. Cezard C*, **Rabbind Singh A***, Le Gac G, Gourlaouen I, Ferec C, and Rochette J. Phenotypic expression of a novel C282Y/R226G compound heterozygous state in HFE hemochromatosis: molecular dynamics and biochemical studies. *Blood cells, molecules & diseases* 52: 27-34, 2014. (***first authors**)
3. Morin G*, Bruechle NO*, **Rabbind Singh A***[§], Knopp C, Jedraszak G, Elbracht M, Bremond-Gignac D, Hartmann K, Sevestre H, Deutz P, Herent D, Nurnberg P, Romeo B, Konrad K, Mathieu-Dramard M, Oldenburg J, Bourges-Petit E, Shen Y, Zerres K, Ouadid-Ahidouch H, and Rochette J [§]. Gain-of-Function Mutation in STIM1 (P.R304W) is Associated with Stormorken Syndrome. *Human mutation* 35: 1221-1232, 2014. (***first author's**, [§]**Corresponding author's**)
4. **Rabbind Singh A***, Morin G, Rochette J. Stormorken syndrome or York platelet syndrome: A clinician's dilemma. *Molecular Genetics and Metabolism Reports* 2: 80. 2015 (***Corresponding author**)
5. Anbazhagan K, **Rabbind Singh A**, Isabelle P, Stella I, Celine AD, Bissac E, Bertrand B, Remy N, Naomi T, Vincent F, Rochette J, and Lassoued K. Human pre-B cell receptor signal transduction: evidence for distinct roles of PI3 kinase and MAP-kinase signalling pathways. *Immunity, inflammation and disease* 1: 26-36, 2013.
6. Marcq I, Nyga R, Cartier F, **Rabbind Singh A**, Ossart C, Ouled-Haddou H, Ghamlouch H, Galmiche A, Chatelain D, Lamotte L, Debuysscher V, Fuentes V, Nguyen-Khac E, Regimbeau JM, Marolleau JP, Latour S, and Bouhlal H. Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression. *PloS one* 8: e82918, 2013.
7. Delcourt M, Riant F, Mancini J, Milh M, Navarro V, Roze E, Humbertclaude V, Korff C, Des Portes V, Szepetowski P, Doummar D, Echenne B, Quintin S, Leboucq N, **Rabbind Singh A**, Rochette J, and Roubertie A. Severe phenotypic spectrum of biallelic mutations in PRRT2 gene. *Journal of neurology, neurosurgery, and psychiatry* 86, 782-785, 2015.

8. Ghamlouch H, Darwiche W, Hodroge A, Ouled-Haddou H, Dupont S, **Rabbind Singh A**, Guignant C, Trudel S, Royer B, Gubler B, Marolleau J. Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells. *Oncotarget* 6, 18484-18503, 2015.
9. Jedraszak G, Braun K, Receveur A, Decamp M, Andrieux J, **Rabbind Singh A**, Copin H, Bremond-Gignac D, Mathieu M, Rochette J, and Morin Gilles. Growth Hormone Deficiency and pituitary malformation in a recurrent Cat-Eye syndrome: a family report. *Annales d' Endocrinologie* 76, 629-634, 2015.
10. **Rabbind Singh A***^{\$}, Philippe Lacan* , Estelle Cadet, Patricia Bignet, Cécile Dumesnil, Jean-Pierre Vannier, Philippe Joly and Jacques Rochette^{\$}. A new intergenic alpha globin deletion (α - $\alpha^{\Delta 125}$) found in a kabyle population. *Hemoglobin*.40(2):108-12. 2016 (***first author's, ^{\$}Corresponding author's**)
11. Bouhlal H, Ouled-Haddou H, Debuyscher V, **Rabbind Singh A**, Ossart C, Reignier A, Hocini H, Fouquet G, AL Baghami M, Eugenio MS, Nguyen-Khac E, Regimbeau JM, Marcq I. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. *Oncotarget*. 7(9):9832-43. 2016 (**Co-corresponding author**)
12. Ouled-Haddou H, Debuyscher V, Fouquet G, Eugenio MS, **Rabbind Singh A**, Ossart C, Al Bagami M, Regimbeau JM, Nguyen-Khac E, Marcq I, Bouhlal H. Hepatocyte SLAMF3 reduced specifically the Multi-Drugs Resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. *Oncotarget*. doi: 10.18632/oncotarget.8679. 2016 (**Co-corresponding author**).
13. Gregory Fouquet1, Ingrid Marcq, Véronique Debuyscher, **Amrathlal Rabbind Singh**, Abderrahmane Bengrine, Eric N'Guyen-Khac, Mickael Naassila, Hicham Bouhlal. Signaling Lymphocytic Activation Molecules SLAM and cancers: friends or foes? *Oncotarget* 2017 (minor revision)

ResearchGate Link: https://www.researchgate.net/profile/Amrathlal_Singh